Clinical trial
Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With…
NCT00227305 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00227305 |
|---|---|
| Title | Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder |
| Official title | A 26-week, Multicenter, Open-label Phase 3b Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in Children and Adolescents With Bipolar I Disorder and Adolescents With Schizophrenia (Abbreviated) |
| Acronym | ANCHOR 150 |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia, Bipolar I Disorder |
| Intervention type | Drug |
| Interventions | quetiapine fumarate |
| Enrollment | 381 |
| Start date | Aug 1, 2004 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Sep 28, 2005 |
| Last update posted | Jan 8, 2013 |
| Countries | India, Malaysia, Philippines, Poland, Russia, Serbia, South Africa, Ukraine, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: